mitomycin has been researched along with mk-1775 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arai, T; Hirai, H; Imagaki, K; Iwasawa, Y; Kobayashi, M; Kotani, H; Mizuarai, S; Nishibata, T; Ohtani, J; Okada, M; Sakai, N; Sakai, T; Yoshizumi, T | 1 |
Brody, JR; Chand, SN; Dylgjeri, E; Lal, S; Mambelli-Lisboa, NC; Pishvaian, MJ; Winter, JM; Yeo, CJ; Zarei, M | 1 |
2 other study(ies) available for mitomycin and mk-1775
Article | Year |
---|---|
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Capecitabine; Caspases; Cell Cycle Proteins; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; DNA Damage; Doxorubicin; Flow Cytometry; Fluorouracil; Glutamates; Guanine; Histones; Humans; Immunoenzyme Techniques; Mitomycin; Nuclear Proteins; Pemetrexed; Phosphorylation; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rats; Rats, Inbred F344; Rats, Nude; Xenograft Model Antitumor Assays | 2010 |
WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Mitomycin; Mitosis; Mutagens; Mutation; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones | 2016 |